Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.42 |
| ▸ | DRD3 | P35462 | 7/20 | 0.42 |
| ▸ | HTR1D | P28221 | 3/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.36 |
| ▸ | DRD4 | P21917 | 4/20 | 0.36 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | HTR1B | P28222 | 2/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677895 | 1.00 | DRD2 (0.42) | DRD2DRD3HTR1DHSD11B1CHRM1 | |
| SCHEMBL32677899 | 1.00 | DRD2 (0.42) | DRD2DRD3HTR1DHSD11B1CHRM1 | |
| SCHEMBL26173625 | 0.79 | CCR2 (0.38) | DRD2DRD3HTR1DHSD11B1CHRM1 | |
| SCHEMBL17393794 | 0.76 | HSD11B1 (0.41) | DRD2DRD3HTR1DHSD11B1CHRM1 | |
| SCHEMBL25323536 | 0.76 | DRD2 (0.45) | DRD2DRD3HTR1DCHRM1DRD4 | |
| SCHEMBL15775201 | 0.75 | HSD11B1 (0.38) | DRD2DRD3HTR1DHSD11B1CHRM1 | |
| SCHEMBL15775228 | 0.74 | HSD11B1 (0.40) | DRD2DRD3HTR1DHSD11B1CHRM1 | |
| SCHEMBL3182694 | 0.74 | PDK2 (0.36) | — | |
| SCHEMBL6265978 | 0.74 | DRD2 (0.43) | DRD2DRD3HTR1DHSD11B1CHRM1 | |
| SCHEMBL31415018 | 0.72 | KCNH2 (0.41) | DRD2DRD3HTR1DCHRM1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-17 | — | — | US | disclosed |
| US-RE50455-E1 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-10 | — | — | US | disclosed |
| US-20250092041-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12187724-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20250002494-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-01-02 | — | — | US | disclosed |
| US-20240262824-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-08-08 | — | — | US | disclosed |
| US-20240246971-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-25 | — | — | US | disclosed |
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2928888-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | Hutchison Medipharma Limited (CN) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225604-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DRD2 951/4885DRD3 1130/4885HTR1D 104/4885 |
| US-12410168-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | DRD2 951/4885DRD3 1130/4885HTR1D 104/4885 |
| US-12331049-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | DRD2 951/4885DRD3 1130/4885HTR1D 104/4885 |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | DRD2 1611/4885DRD3 2094/4885HTR1D 1361/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | DRD2 1611/4885DRD3 2094/4885HTR1D 1361/4885 |
| US-20260103463-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DRD2 254/4885DRD3 301/4885HTR1D 45/4885 |
| US-12187724-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | DRD2 951/4885DRD3 1130/4885HTR1D 104/4885 |
| US-20240246971-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DRD2 951/4885DRD3 1130/4885HTR1D 104/4885 |
| US-20250002494-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DRD2 951/4885DRD3 1130/4885HTR1D 104/4885 |
| US-20240262824-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DRD2 951/4885DRD3 1130/4885HTR1D 104/4885 |
| US-12331050-B2 | Pyrazolopyridine derivative having GLP-1 receptor agonist effect | GLP1R, GPR119, GIPR | DRD2 951/4885DRD3 1130/4885HTR1D 104/4885 |
| US-20250092041-A1 | PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT | GLP1R, GPR119, GIPR | DRD2 742/4885DRD3 632/4885HTR1D 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.